Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

(2021) Pan Tang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions

(2021) Minru Liao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors

(2020) Tian Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

(2020) Xiaosa Chang et al.   Acta Pharmaceutica Sinica B

Further Progress for Patients with Breast Cancer

(2019) Daniel F. Hayes   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy

(2019) Chia-Hao Chang et al.   Autophagy

Targeting autophagy-related protein kinases for potential therapeutic purpose

(2019) Honggang Xiang et al.   Acta Pharmaceutica Sinica B

Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson’s Disease Treatment

(2018) Liang Ouyang et al.   JOURNAL OF MEDICINAL CHEMISTRY

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases

(2017) Avileen Kaur et al.   INFLAMMOPHARMACOLOGY

PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy

(2016) Ji-Hoon Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Breast cancer

(2015) Chris Woolston   NATURE

Clinical and molecular complexity of breast cancer metastases

(2015) Siker Kimbung et al.   SEMINARS IN CANCER BIOLOGY

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers

(2014) Sylvain Lefort et al.   Autophagy

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway

(2014) Biyin Cao et al.   Scientific Reports

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2

(2013) Yasuhiro Maejima et al.   NATURE MEDICINE

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

Temsirolimus Activates Autophagy and Ameliorates Cardiomyopathy Caused by Lamin A/C Gene Mutation

(2012) J. C. Choi et al.   Science Translational Medicine

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

Finding a fitting shoe for Cinderella

(2010) Simon Miller et al.   Autophagy

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

(2008) Beth Apsel et al.   Nature Chemical Biology

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE